• 1
    NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19: 146.
  • 2
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 3
    Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470477.
  • 4
    Ferenci P. Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis 2004; 24(Suppl 2): 2531.
  • 5
    Yee LJ. Host genetic determinants in hepatitis C virus infection. Genes Immun 2004; 5: 237245.
  • 6
    Chung RT, Gale M, Jr., Polyak SJ, Lemon SM, Liang TJ, Hoofnagle JH. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: summary of a workshop. HEPATOLOGY 2008; 47: 306320.
  • 7
    Barnes E, Harcourt G, Brown D, Lucas M, Phillips R, Dusheiko G, et al. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. HEPATOLOGY 2002; 36: 743754.
  • 8
    Hoffmann RM, Diepolder HM, Zachoval R, Zwiebel FM, Jung MC, Scholz S, et al. Mapping of immunodominant CD4+ T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. HEPATOLOGY 1995; 21: 632638.
  • 9
    Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004; 25: 472492.
  • 10
    Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR, et al. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006; 131: 14401451.
  • 11
    Morgan TR, Lambrecht RW, Bonkovsky HL, Chung RT, Naishadham D, Sterling RK, et al. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol 2008; 49: 548556.
  • 12
    Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 10151023; discussion 1947.
  • 13
    Packer BR, Yeager M, Staats B, Welch R, Crenshaw A, Kiley M, et al. SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes. Nucl Acids Res 2004; 32: D528D532.
  • 14
    Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York, NY: John Wiley and Sons; 2000.
  • 15
    Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadephia: Lippincott-Raven Publishers; 1998: 256.
  • 16
    Clemens MJ, Elia A. The double-stranded RNA-dependent protein kinase PKR: structure and function. J Interferon Cytokine Res 1997; 17: 503524.
  • 17
    Tan SL, Katze MG. The emerging role of the interferon-induced PKR protein kinase as an apoptotic effector: a new face of death? J Interferon Cytokine Res 1999; 19: 543554.
  • 18
    Foy E, Li K, Wang C, Sumpter R, Jr., Ikeda M, Lemon SM, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300: 11451148.
  • 19
    Nakaya T, Sato M, Hata N, Asagiri M, Suemori H, Noguchi S, et al. Gene induction pathways mediated by distinct IRFs during viral infection. Biochem Biophys Res Commun 2001; 283: 11501156.
  • 20
    Su X, Yee LJ, Im K, Rhodes SL, Tang Y, Tong X, et al. Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. J Hepatol 2008; 49: 184191.
  • 21
    Hazari S, Taylor L, Haque S, Garry R, Florman S, Luftig R, et al. Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in hepatitis C virus replicon. Virol J 2007; 4: 89.
  • 22
    Hijikata M, Ohta Y, Mishiro S. Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt –88) correlated with the response of hepatitis C patients to interferon. Intervirology 2000; 43: 124127.
  • 23
    Suzuki F, Arase Y, Suzuki Y, Tsubota A, Akuta N, Hosaka T, et al. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J Viral Hepat 2004; 11: 271276.
  • 24
    Knapp S, Yee LJ, Frodsham AJ, Hennig BJW, Hellier S, Zhang L, et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun 2003; 4: 411419.
  • 25
    Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990; 1: 4346.
  • 26
    McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JPA, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008; 9: 356369.
  • 27
    Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, Zhu J, et al. Genetics of gene expression and its effect on disease. Nature 2008; 452: 423428.
  • 28
    Heinzen EL, Ge D, Cronin KD, Maia JM, Shianna KV, Gabriel WN, et al. Tissue-specific genetic control of splicing: implications for the study of complex traits. PLoS Biol 2008; 6: e1.